Quince Therapeutics Appoints Five Experts to Advance LAM-001 for Pulmonary Diseases
QNCX•Quince Therapeutics formed a Scientific Advisory Board of five leading pulmonary medicine experts to support development of LAM-001, an inhaled rapamycin formulation aimed at enhancing pulmonary delivery and reducing systemic exposure. The SAB will guide clinical advancement of LAM-001 across pulmonary hypertension associated with interstitial lung disease, bronchiolitis obliterans syndrome post–lung transplant and sarcoidosis-associated pulmonary hypertension.
1. Formation and Mandate of SAB
Quince Therapeutics announced the establishment of a Scientific Advisory Board comprising five internationally recognized pulmonary medicine experts to support the development of LAM-001. The board is tasked with advising on clinical strategy, trial design and translational research to optimize pulmonary delivery and minimize systemic exposure.
2. Focus on LAM-001 Development
LAM-001 is an inhaled formulation of the mTOR inhibitor rapamycin designed to target serious pulmonary conditions by delivering the drug directly to lung tissue. The program aims to address pulmonary hypertension associated with interstitial lung disease, bronchiolitis obliterans syndrome post–lung transplant and sarcoidosis-associated pulmonary hypertension.
3. Profiles of Key Advisory Members
The SAB is chaired by Paul Yu, M.D., Ph.D., of Massachusetts General Hospital, and includes Aaron Waxman, M.D., Ph.D., Steven Nathan, M.D., Steve Hays, M.D., and Robert Baughman, M.D. Each member brings extensive clinical trial experience and expertise in pulmonary vascular disease, lung transplantation and rare lung disorders.
4. Strategic Implications for Quince
By leveraging the SAB’s expertise, Quince aims to accelerate LAM-001 toward clinical milestones and differentiate its therapy in underserved pulmonary indications. The board’s guidance could de-risk development pathways and enhance the product’s positioning alongside existing treatment options.
